Patent protection secured in key markets

Aptahem has established a comprehensive knowledge management system through which new ideas, methods and results are systematically codified. The company’s intellectual property portfolio consists of both approved patents and filed patent applications based on unique new chemical compounds in the form of unique RNA aptamer-based drug candidates. The drug candidates are protected by the strongest form of patent protection in the pharmaceutical industry, i.e. compound matter patent.

For new patentable technology, Aptahem strategically plans to apply for patents in countries that are expected to become key markets for the company in the future. Currently, the following markets are being considered: Europe, the US, Canada, China, Japan and India. The company intends to apply for additional patents in the event that Aptahem considers that the company should strengthen the intellectual property portfolio further.

Aptahem’s intellectual property rights portfolio currently consists of two patent families that are fully-owned by the company. First patent family, as mentioned above, and the second family was filed based on the therapeutic applications and mechanism of the company’s lead candidate, Apta-1. Patent family 2 has been approved in several strategically important geographical areas, and is pending in a few others. This patent family will be updated as new results are collected, which strenghthens the protection further.

Also, new patent opportunities are constantly investigated by the company.

Patent family 1

RegionApplication number/ Registration numberApplication dateExpiration dateStatus
Canada27141212009-02-052029-02-05Granted
ChinaZL200980111646.42009-02-052029-02-05Granted
France2 247 7282009-02-052029-02-05Granted
Germany2 247 7282009-02-052029-02-05Granted
Great Britain2 247 7282009-02-052029-02-05Granted
India3530242009-02-052029-02-05Granted
Italy5020150000183902009-02-052029-02-05Granted
Spain2 247 7282009-02-052029-02-05Granted
Sweden2 247 7282009-02-052029-02-05Granted
Switzerland2 247 7282009-02-052029-02-05Granted
USA12/8664132009-02-052029-02-05Granted

Patent family 2

RegionApplication number/ Patent numberApplication date*Expiration dateStatus
Austria36916552018-10-032038-10-03Granted
Brazil11 2020 005995 12018-10-032038-10-03Pending
Canada30733642018-10-032038-10-03Pending
China20188006431062018-10-032038-10-03Pending
France36916552018-10-032038-10-03Granted
Germany602018022979.52018-10-032038-10-03Granted
Great Britain36916552018-10-032038-10-03Granted
Israel2737592018-10-032038-10-03Granted
Italy5020210000802762018-10-032038-10-03Granted
Japan70255372018-10-032038-10-03Granted
The Netherlands36916552018-10-032038-10-03Granted
Poland36916552018-10-032038-10-03Granted
South Korea10-2020-70072662018-10-032038-10-03Pending
Spain36916552018-10-032038-10-03Granted
Sweden36916552018-10-032038-10-03Granted
Switzerland36916552018-10-032038-10-03Granted
TurkeyTR 2021/013877 T42018-10-032038-10-03Granted
USA16/652,9262018-10-032038-10-03Granted

*PCT application